Human DNA-topoisomerases - Diagnostic and therapeutic implications for cancer

Onkologie

Volumn 23, Issue 5, 2000, Pages 424-430

  Kellner, U ^a   Rudolph, P ^b   Parwaresch, R ^b  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

Topo I; Topo II ; Topo II ; Topoisomerase inhibitors

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAMPTOTHECIN; DAUNORUBICIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; GYRASE INHIBITOR; IDARUBICIN; IRINOTECAN; MITOXANTRONE; PODOPHYLLOTOXIN DERIVATIVE; TENIPOSIDE; TOPOTECAN;

BLOOD TOXICITY; CANCER DIAGNOSIS; CANCER SURVIVAL; CANCER THERAPY; CELL CYCLE; CELL PROLIFERATION; DNA REPLICATION; ENZYME ACTIVITY; ENZYME ANALYSIS; GENE LOCUS; HUMAN; PROGNOSIS; PROTEIN EXPRESSION; REVIEW;

EID: 0033659273     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000027205     Document Type: Review

References (74)

1. Interaction between DNA and an Escherichia coli protein omega
2. cDNA cloning of human DNA topoisomerase I: Catalytic activity of a 67.7-kDa carboxyl-terminal fragment
3. Identification of an N-terminal domain of eukaryotic DNA topoisomerase I dispensable for catalytic activity but essential for in vivo function
4. Microinjection of anti-topoisomerase I immunoglobulin G into nuclei of Chironomus tentans salivary gland cells leads to blockage of transcription elongation
5. The cell cycle effects of camptothecin
6. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: Demonstration of tumor-type specificity and implications for cancer chemotherapy
7. Importance of DNA topoisomerase I expression for sensitivity to cytostatic drugs
8. Differentiating agents modulate topoisomerase I activity in U-937 promonocytic cells
9. DNA gyrase: An enzyme that introduces superhelical turns into DNA
10. Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22
11. Cloning and characterization of the 5'-flanking region of the human topoisomerase II alpha gene
12. Proliferation dependence of topoisomerase II mediated drug action
13. Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24
14. Active heterodimers are formed from human DNA topoisomerase II alpha and II beta isoforms
15. Detection of human topoisomerase II alpha in cell lines and tissues: Characterization of five novel monoclonal antibodies
16. Chromosome recombination and defective genome segregation induced in Chinese hamster cells by the topoisomerase II inhibitor VM-26
17. DNA topoisomerase II mutant of Saccharomyces cerevisiae: Topoisomerase II is required for segregation of daughter molecules at the termination of DNA replication
18. DNA topoisomerase II is required for formation of mitotic chromosomes in Chinese hamster ovary cells: Studies using the inhibitor 4'-demethylepipodophyllotoxin 9-(4.6-O-thenylidene-beta-D-glucopyranoside)
19. Phosphorylation of DNA topoisomerase II by casein kinase II: Modulation of eukaryotic topoisomerase II activity in vitro
20. Phosphorylation of DNA topoisomerase II in a human tumor cell line
21. Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions
22. Prognostic relevance of a novel proliferation marker, Ki-S11, for soft-tissue sarcoma. A multivariate study
23. Amplification of the topoisomerase II alpha gene in a non-small cell lung cancer cell line and characterisation of polymorphisms at the human topoisomerase II alpha and beta loci in normal tissue. Genes Chromosomes
24. Topoisomerase II alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: Relationship to m-AMSA and mitoxantrone sensitivity
25. Plant antitumor agents. 1. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata
26. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I
27. New technique for uncoupling the cleavage and religation reactions of eukaryotic topoisomerase I. The mode of action of camptothecin at a specific recognition site
28. Modification of the hydroxy lactone ring of camptothecin: Inhibition of mammalian topoisomerase I and biological activity
29. Overexpression of human topoisomerase I in baby hamster kidney cells: Hypersensitivity of clonal isolates to camptothecin
30. Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity
31. DNA fragmentation induced by protease activation in p53-null human leukemia HL60 cells undergoing apoptosis following treatment with the topoisomerase I inhibitor camptothecin: Cell-free system studies
32. Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin
33. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880)
34. Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor
35. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study
36. Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel
37. The use of topoisomerase I inhibitors in multiple myeloma
38. Topotecan in pediatric patients with recurrent and progressive solid tumors: A Pediatric Oncology Group phase II study
39. The role of topoisomerase-I inhibitors in the treatment of non-Hodgkin's lymphoma
40. Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: A National Cancer Institute of Canada Clinical Trials Group Study
41. A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo
42. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients
43. Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study
44. Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients
45. Decreased drug accumulation in a mitoxantrone-resistant gastric carcinoma cell line in the absence of P-glycoprotein
46. Atypical multidrug resistance: Breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines
47. Studies of topoisomerase-specific antitumor drugs in human lymphocytes using rabbit antisera against recombinant human topoisomerase II polypeptide
48. Camptothecin hyper-resistant P388 cells: Drug-dependent reduction in topoisomerase I content
49. Increased expression of DNA topoisomerase I gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells
50. Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11
51. Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine
52. Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9-nitro-camptothecin
53. The clinical pharmacology of etoposide
54. Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer
55. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II
56. Relationship of DNA topoisomerase II alpha and beta expression to cytotoxicity of antineoplastic agents in human acute lymphoblastic leukemia cell lines
57. Role of topoisomerase II beta in the resistance of 9-OH-ellipticine-resistant Chinese hamster fibroblasts to topoisomerase II inhibitors
58. Differential induction of secondary DNA fragmentation by topoisomerase II inhibitors in human tumor cell lines with amplified c-myc expression
59. Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines
60. Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer
61. Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells
62. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance
63. Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II
64. Molecular cloning and identification of a point mutation in the topoisomerase II cDNA from an etoposide-resistant Chinese hamster ovary cell line
65. Effect of inhibitors of poly(ADP-ribose) polymerase on the induction of GRP78 and subsequent development of resistance to etoposide
66. Selective use of an alternative stop codon and polyadenylation signal within intron sequences leads to a truncated topoisomerase II alpha messenger RNA and protein in human HL-60 leukemia cells selected for resistance to mitoxantrone
67. Characterization of camptothecin-resistant Chinese hamster lung cells [erratum appears in Biochem Pharmacol 1993;45:787]
68. Expression of DNA topoisomerase I in neoplasms of the kidney: Correlation with histological grade, proliferation, and patient survival
69. Expression of DNA topoisomerase I and DNA topoisomerase II-alpha in carcinoma of the colon
70. KiS1 - A novel monoclonal antibody which recognizes proliferating cells: Evaluation of its relationship to prognosis in mammary carcinoma [erratum appears in J Pathol 1993;169:287]
71. Proliferation marker Ki-S1 binds to a formalin-resistant epitope of topoisomerase II
72. Prognostic significance of ki-67 and topoisomerase IIalpha expression in infiltrating ductal carcinoma of the breast
73. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer
74. Characterization of camptothecin-resistant Chinese hamster lung cells [erratum appears in Biochem Pharmacol 1993;45:787]